{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:41:35Z","timestamp":1765546895960},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,24]]},"DOI":"10.7759\/cureus.23456","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T21:48:19Z","timestamp":1648158499000},"source":"Crossref","is-referenced-by-count":3,"title":["Adverse Reaction to COVID-19 mRNA Vaccination in a Patient With VEXAS Syndrome"],"prefix":"10.7759","author":[{"given":"Giulio","family":"Ciprian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck DB","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, et al.. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020, 383:2628-38. 10.1056\/NEJMoa2026834","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010286","article-title":"Novel somatic mutations in UBA1 as a cause of VEXAS syndrome","volume":"137","author":"Poulter JA","year":"2021","unstructured":"Poulter JA, Collins JC, Cargo C, et al.. Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood. 2021, 137:3676-81. 10.1182\/blood.2020010286","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112082","article-title":"Structural model of the hUbA1-UbcH10 quaternary complex: in silico and experimental analysis of the protein-protein interactions between E1, E2 and ubiquitin","volume":"9","author":"Correale S","year":"2014","unstructured":"Correale S, de Paola I, Morgillo CM, et al.. Structural model of the hUbA1-UbcH10 quaternary complex: in silico and experimental analysis of the protein-protein interactions between E1, E2 and ubiquitin. PLoS One. 2014, 9:e112082. 10.1371\/journal.pone.0112082","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029208","article-title":"Largazole and its derivatives selectively inhibit ubiquitin activating enzyme (e1)","volume":"7","author":"Ungermannova D","year":"2012","unstructured":"Ungermannova D, Parker SJ, Nasveschuk CG, et al.. Largazole and its derivatives selectively inhibit ubiquitin activating enzyme (e1). PLoS One. 2012, 7:e29208. 10.1371\/journal.pone.0029208","journal-title":"PLoS One"},{"key":"ref5","unstructured":"UBA1 ubiquitin like modifier activating enzyme 1 [ Homo sapiens (human) ]. (2022). Accessed. February 5, 2022: https:\/\/www.ncbi.nlm.nih.gov\/sites\/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=7317."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.014","article-title":"Adult-onset autoinflammation caused by somatic mutations in UBA1: aDutch case series of patients with VEXAS","volume":"149","author":"van der Made CI","year":"2022","unstructured":"van der Made CI, Potjewijd J, Hoogstins A, et al.. Adult-onset autoinflammation caused by somatic mutations in UBA1: aDutch case series of patients with VEXAS. J Allergy Clin Immunol. 2022, 149:432-439.e4. 10.1016\/j.jaci.2021.05.014","journal-title":"J Allergy Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3344","article-title":"UBA1 variations in neutrophilic dermatosis skin lesions of patients with VEXAS syndrome","volume":"157","author":"Zakine E","year":"2021","unstructured":"Zakine E, Schell B, Battistella M, et al.. UBA1 variations in neutrophilic dermatosis skin lesions of patients with VEXAS syndrome. JAMA Dermatol. 2021, 157:1349-54. 10.1001\/jamadermatol.2021.3344","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000661","article-title":"Azacytidine treatment for VEXAS syndrome","volume":"5","author":"Raaijmakers MH","year":"2021","unstructured":"Raaijmakers MH, Hermans M, Aalbers A, Rijken M, Dalm VA, van Daele P, Valk PJ. Azacytidine treatment for VEXAS syndrome. Hemasphere. 2021, 5:e661. 10.1097\/HS9.0000000000000661","journal-title":"Hemasphere"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800149","article-title":"Case report: genetic double strike: VEXAS and TET2-positive myelodysplastic syndrome in a patient with long-standing refractory autoinflammatory disease","volume":"12","author":"L\u00f6tscher F","year":"2021","unstructured":"L\u00f6tscher F, Seitz L, Simeunovic H, et al.. Case report: genetic double strike: VEXAS and TET2-positive myelodysplastic syndrome in a patient with long-standing refractory autoinflammatory disease. Front Immunol. 2021, 12:800149. 10.3389\/fimmu.2021.800149","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.715878","article-title":"Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines","volume":"8","author":"Pastori D","year":"2021","unstructured":"Pastori D, Menichelli D, Cammisotto V, Pignatelli P. Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines. Front Cardiovasc Med. 2021, 8:715878. 10.3389\/fcvm.2021.715878","journal-title":"Front Cardiovasc Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20910855","article-title":"An update on the management of antiphospholipid syndrome","volume":"12","author":"Rodziewicz M","year":"2020","unstructured":"Rodziewicz M, D'Cruz DP. An update on the management of antiphospholipid syndrome. Ther Adv Musculoskelet Dis. 2020, 12:1759720X20910855. 10.1177\/1759720X20910855","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou MG","year":"2019","unstructured":"Tektonidou MG, Andreoli L, Limper M, et al.. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019, 78:1296-304. 10.1136\/annrheumdis-2019-215213","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220876","article-title":"Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan","volume":"80","author":"Kirino Y","year":"2021","unstructured":"Kirino Y, Takase-Minegishi K, Tsuchida N, Hirahara L, Kunishita Y, Yoshimi R, Nakajima H. Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan. Ann Rheum Dis. 2021, 80:1501-2. 10.1136\/annrheumdis-2021-220876","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1590334","article-title":"Tocilizumab for the treatment of adult-onset Still's disease","volume":"19","author":"Casta\u00f1eda S","year":"2019","unstructured":"Casta\u00f1eda S, Mart\u00ednez-Quintanilla D, Mart\u00edn-Varillas JL, Garc\u00eda-Casta\u00f1eda N, Atienza-Mateo B, Gonz\u00e1lez-Gay MA. Tocilizumab for the treatment of adult-onset Still's disease. Expert Opin Biol Ther. 2019, 19:273-86. 10.1080\/14712598.2019.1590334","journal-title":"Expert Opin Biol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nature15252","article-title":"Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6","volume":"525","author":"Zhang Q","year":"2015","unstructured":"Zhang Q, Zhao K, Shen Q, et al.. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015, 525:389-93. 10.1038\/nature15252","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in VEXAS syndrome: insights from a retrospective series","volume":"137","author":"Bourbon E","year":"2021","unstructured":"Bourbon E, Heiblig M, Gerfaud Valentin M, et al.. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood. 2021, 137:3682-4. 10.1182\/blood.2020010177","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2021.09.001","article-title":"Toward a pathophysiology inspired treatment of VEXAS syndrome","volume":"58","author":"Heiblig M","year":"2021","unstructured":"Heiblig M, Patel BA, Groarke EM, Bourbon E, Sujobert P. Toward a pathophysiology inspired treatment of VEXAS syndrome. Semin Hematol. 2021, 58:239-46. 10.1053\/j.seminhematol.2021.09.001","journal-title":"Semin Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004749","article-title":"Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience","volume":"6","author":"Diarra A","year":"2022","unstructured":"Diarra A, Duployez N, Fournier E, et al.. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv. 2022, 6:998-1003. 10.1182\/bloodadvances.2021004749","journal-title":"Blood Adv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/89090-adverse-reaction-to-covid-19-mrna-vaccination-in-a-patient-with-vexas-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:43:09Z","timestamp":1707507789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/89090-adverse-reaction-to-covid-19-mrna-vaccination-in-a-patient-with-vexas-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.23456","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,24]]}}}